Early Real-World First-Line Treatment With Venetoclax Plus HMAs Versus HMA Monotherapy Among Patients With AML in a Predominately US Community Setting
- Resource Type
- Article
- Source
- In
Clinical Lymphoma, Myeloma and Leukemia May 2023 23(5):e222-e231 - Subject
- Language
- ISSN
- 2152-2650